These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. [Advances in the treatment of juvenile myelomonocytic leukemia]. Cai YL; Zhang JL; Zhu XF Zhongguo Dang Dai Er Ke Za Zhi; 2018 Nov; 20(11):958-963. PubMed ID: 30477631 [TBL] [Abstract][Full Text] [Related]
24. NUP98-NSD1 Driven MDS/MPN in Childhood Masquerading as JMML. Behnert A; Lee AG; Young EP; Breese MR; Leung SG; Behroozfard I; Maruffi M; Sweet-Cordero EA; Dvorak CC; Chu J; Stieglitz E J Pediatr Hematol Oncol; 2021 Aug; 43(6):e808-e811. PubMed ID: 32815876 [TBL] [Abstract][Full Text] [Related]
25. Clinical course of juvenile myelomonocytic leukemia in the blast crisis phase treated by acute myeloid leukemia-oriented chemotherapy and allogeneic hematopoietic stem cell transplantation. Ueda S; Sakata N; Muramatsu H; Sakaguchi H; Wang X; Xu Y; Kojima S; Yamaguchi T; Higa T; Takemura T Int J Hematol; 2014 Nov; 100(5):502-6. PubMed ID: 25047104 [TBL] [Abstract][Full Text] [Related]
26. Inflammatory response in hematopoietic stem and progenitor cells triggered by activating SHP2 mutations evokes blood defects. Solman M; Blokzijl-Franke S; Piques F; Yan C; Yang Q; Strullu M; Kamel SM; Ak P; Bakkers J; Langenau DM; Cavé H; den Hertog J Elife; 2022 May; 11():. PubMed ID: 35535491 [TBL] [Abstract][Full Text] [Related]
27. [Molecular mechanism and progress in treatment of juvenile myelomonocytic leukemia (JMML)]. Koike K; Matsuda K Rinsho Ketsueki; 2013 Jun; 54(6):538-44. PubMed ID: 23823092 [No Abstract] [Full Text] [Related]
28. Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML. Yoshimi A; Balasis ME; Vedder A; Feldman K; Ma Y; Zhang H; Lee SC; Letson C; Niyongere S; Lu SX; Ball M; Taylor J; Zhang Q; Zhao Y; Youssef S; Chung YR; Zhang XJ; Durham BH; Yang W; List AF; Loh ML; Klimek V; Berger MF; Stieglitz E; Padron E; Abdel-Wahab O Blood; 2017 Jul; 130(4):397-407. PubMed ID: 28576879 [TBL] [Abstract][Full Text] [Related]
29. RAS Pathway Mutation Patterns in Patients With Juvenile Myelomonocytic Leukemia: A Developing Country Single-center Experience. Hamdy N; Bokhary H; Elsayed A; Hozayn W; Soliman S; Salem S; Alsheshtawi K; Abdalla A; Hafez H; Hammad M Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):e368-e374. PubMed ID: 32209330 [TBL] [Abstract][Full Text] [Related]
30. Despite mutation acquisition in hematopoietic stem cells, JMML-propagating cells are not always restricted to this compartment. Caye A; Rouault-Pierre K; Strullu M; Lainey E; Abarrategi A; Fenneteau O; Arfeuille C; Osman J; Cassinat B; Pereira S; Anjos-Afonso F; Currie E; Ariza-McNaughton L; Barlogis V; Dalle JH; Baruchel A; Chomienne C; Cavé H; Bonnet D Leukemia; 2020 Jun; 34(6):1658-1668. PubMed ID: 31776464 [TBL] [Abstract][Full Text] [Related]
31. Inhibition of SRC corrects GM-CSF hypersensitivity that underlies juvenile myelomonocytic leukemia. Bunda S; Kang MW; Sybingco SS; Weng J; Favre H; Shin DH; Irwin MS; Loh ML; Ohh M Cancer Res; 2013 Apr; 73(8):2540-50. PubMed ID: 23400592 [TBL] [Abstract][Full Text] [Related]
32. Current management of juvenile myelomonocytic leukemia and the impact of RAS mutations. Yoshida N; Doisaki S; Kojima S Paediatr Drugs; 2012 Jun; 14(3):157-63. PubMed ID: 22480363 [TBL] [Abstract][Full Text] [Related]
33. How I treat juvenile myelomonocytic leukemia. Locatelli F; Niemeyer CM Blood; 2015 Feb; 125(7):1083-90. PubMed ID: 25564399 [TBL] [Abstract][Full Text] [Related]
34. [Allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia and juvenile myelomonocytic leukemia]. Shao Q; Wang ZD; Zheng XL; Dong L; Han DM; Yan HM; Wang HX; Duan LN Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Aug; 22(4):1058-62. PubMed ID: 25130828 [TBL] [Abstract][Full Text] [Related]
35. Therapy-related myeloid neoplasms resembling juvenile myelomonocytic leukemia: a case series and review of the literature. Wintering A; Smith S; Fuh B; Rangaswami A; Dahl G; Chien M; Gruber TA; Dang J; Li LS; Lenzen A; Savelli S; Dvorak CC; Agrawal AK; Stieglitz E Pediatr Blood Cancer; 2022 May; 69(5):e29499. PubMed ID: 34939322 [TBL] [Abstract][Full Text] [Related]
36. Anti-proliferative effects of T cells expressing a ligand-based chimeric antigen receptor against CD116 on CD34(+) cells of juvenile myelomonocytic leukemia. Nakazawa Y; Matsuda K; Kurata T; Sueki A; Tanaka M; Sakashita K; Imai C; Wilson MH; Koike K J Hematol Oncol; 2016 Mar; 9():27. PubMed ID: 26983639 [TBL] [Abstract][Full Text] [Related]
37. JMML genomics and decisions. Niemeyer CM Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):307-312. PubMed ID: 30504325 [TBL] [Abstract][Full Text] [Related]
38. Juvenile myelomonocytic leukemia with t(3;5)(q25;q35), Auer rods and marked myelodysplasia. Li W; Cooley LD; August K Pathol Res Pract; 2018 Jun; 214(6):919-923. PubMed ID: 29496305 [TBL] [Abstract][Full Text] [Related]